A Critical Update on Therapy Selection, Sequencing, and Toxicity Management of Novel Therapies for Multiple Myeloma

To participate in this activity, please:

In this program, Sagar Lonial, MD, a nationally recognized expert in multiple myeloma, guides participants through a series of clinical questions centered around four patient cases. These cases serve as a framework for exploring risk stratification, treatment selection, and adverse effect management in patients with multiple myeloma. Faculty member, Dr. Lonial, provides responses to these clinical questions, offering valuable insights and evidence-based recommendations. Dr. Lonial's extensive research and clinical experience in the field enable him to share best practices and clinical pearls for managing relapsed/refractory multiple myeloma in adults. The program format fosters interactive discussions, allowing participants to engage with the patient cases and benefit from the expertise of the faculty.

Course Credit:

1 AMA PRA Category 1 CreditTM
1 ANCC Contact Hour
1 Pharmacology Hour


Opens: 2023-05-25
Closes: 2024-05-25

Target Audience:

This activity is intended for hematologist-oncologists, advanced practitioners, oncology nurses, pharmacists, and other healthcare professionals involved in the care of patients diagnosed with multiple myeloma.

This activity is supported by educational grants from Sanofi and Karyopharm.


In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 contact hour, including 1 pharmacology hour.

Additional Content Planners

James Davis, PharmD, BCOP (Medical Writer)
No significant relationships to disclose.

Heather Jimenez, MSN, FNP-C (Nurse Planner)
No significant relationships to disclose.

Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Sagar Lonial, MD, FACP

    Chair and Professor
    Department of Hematology and Medical Oncology
    Anne and Bernard Gray Family Chair in Cancer
    Chief Medical Officer
    Winship Cancer Institute
    Emory University School of Medicine
    Atlanta, Georgia

Learning Objectives

  • Illustrate the use of risk stratification in treatment selection for front-line multiple myeloma
  • Implement treatment strategies for patients with early-relapse multiple myeloma
  • Evaluate current guidelines and emerging clinical data for relapsed/refractory multiple myeloma
  • Identify appropriate management strategies for adverse effects associated with novel-targeted therapies

Faculty Disclosures

Sagar Lonial, MD, FACP

Advisory Board: AbbVie, Amgen, BMS, Genentech, Janssen, Novartis, Pfizer, Takeda

Board of Directors: TG Therapeutics